Galenica records solid growth in 2025 and adjusts its forecasts

Galenica AG announced a 5.5% increase in revenue for 2025, reaching CHF 4,135.6 million, with positive contributions from all business areas. Adjusted EBIT rose by 11.3% to CHF 234.8 million. The pharmacy network was strengthened through the expansion of advisory services, while the modernization of wholesale systems increased efficiency. Galenica laid the groundwork for future growth in the diagnostics and home healthcare sectors through strategic acquisitions.

For 2026, Galenica anticipates revenue growth of 5% to 7% and adjusted EBIT growth of 6% to 8%. The medium-term outlook has been revised upwards, with an adjusted EBIT target of CHF 270 million by 2027. The strong financial performance also allows for a proposed increased dividend, underscoring the company's ambition for continued and sustainable growth.